Clinical Trials Directory

Trials / Completed

CompletedNCT04036669

Adipokines as Predictors of Foot Function, Pain, and Disability in Patients With Rheumatoid Arthritis

Foot Bone Mineral Density and Inflammation in Rheumatoid Arthritis

Status
Completed
Phase
Study type
Observational
Enrollment
160 (actual)
Sponsor
King Saud University · Academic / Other
Sex
All
Age
35 Years – 60 Years
Healthy volunteers
Accepted

Summary

Significant increase in the levels of serum adiponectin, ADA, and hsCRP was reported in all RA patients compared to controls. Compared to patients with early RA, the increase in these markers significantly correlated with disease activity (DAS-ESR), lower f-BMD, radiographic scoring, pain, FFI, and functional limitations in patients with established RA. Adiponectin showed a negative correlation with serum levels of both ADA and hsCRP. By using ROC curve analysis, optimal cut-off values of adiponectin (28.8 µg/ml), ADA (27.3 IU/L), and hsCRP (1.6 mg/L) could be used to estimate early RA in 45 % of the patients. Similarly, using cut-off values of adiponectin (32.8 µg/ml), ADA (26.1 IU/L ml), and hsCRP (2.5 mg/L), established RA could be predicted in 55 % of patients with 98-99% accuracy.

Detailed description

The present study attempts to evaluate the efficacy of adiponectin, ADA, and foot bone mineral density (fBMD) as predictors of the disease progression in patients with rheumatoid arthritis. A total of 80 RA patients and eighty age and sex-matched healthy controls were included in this study.

Conditions

Timeline

Start date
2014-02-20
Primary completion
2015-04-30
Completion
2015-05-30
First posted
2019-07-30
Last updated
2019-07-30

Source: ClinicalTrials.gov record NCT04036669. Inclusion in this directory is not an endorsement.